Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Brief description of study

This is a randomized phase III study evaluating the benefit of nivolumab (a PD-1 blocking antibody) versus observation for patients with stage IB > 4cm, II and IIIA NSCLC following surgical resection.  Patients will enroll onto this trial after surgery for their disease and after receiving any standard post-operative therapy. Duration of therapy on this trial is one year. The co-primary endpoints of this trial are overall survival and disease-free survival. Secondary objectives include toxicity and safety of nivolumab.


Clinical Study Identifier: s16-02074
ClinicalTrials.gov Identifier: NCT02595944
Principal Investigator: Elaine Shum
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.